Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Hims & Hers Health Inc (HIMS)

Hims & Hers Health Inc (HIMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,646,049
  • Shares Outstanding, K 227,939
  • Annual Sales, $ 2,348 M
  • Annual Income, $ 128,370 K
  • EBIT $ 106 M
  • EBITDA $ 163 M
  • 60-Month Beta 2.55
  • Price/Sales 2.40
  • Price/Cash Flow 29.60
  • Price/Book 10.41

Options Overview Details

View History
  • Implied Volatility 99.44% (+0.75%)
  • Historical Volatility 138.43%
  • IV Percentile 63%
  • IV Rank 52.72%
  • IV High 135.37% on 04/08/25
  • IV Low 59.38% on 12/31/25
  • Expected Move (DTE 5) 2.33 (9.40%)
  • Put/Call Vol Ratio 0.59
  • Today's Volume 287,802
  • Volume Avg (30-Day) 228,793
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 1,418,797
  • Open Int (30-Day) 1,084,797
  • Expected Range 22.44 to 27.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.02
  • Number of Estimates 4
  • High Estimate 0.04
  • Low Estimate -0.02
  • Prior Year 0.20
  • Growth Rate Est. (year over year) -90.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.74 +80.28%
on 02/24/26
27.54 -10.06%
on 03/11/26
+8.47 (+51.96%)
since 02/13/26
3-Month
13.74 +80.28%
on 02/24/26
38.03 -34.87%
on 12/15/25
-12.44 (-33.43%)
since 12/12/25
52-Week
13.74 +80.28%
on 02/24/26
70.43 -64.83%
on 07/31/25
-6.77 (-21.46%)
since 03/13/25

Most Recent Stories

More News
MarketBeat Week in Review – 03/09 - 03/13

Stocks moved higher this week despite uncertainty over the Iran conflict and oil prices; economic indicators point to no change in interest rates next week

GOOGL : 302.28 (-0.42%)
NVDA : 180.25 (-1.58%)
AVGO : 322.16 (-4.11%)
TJX : 155.43 (-0.23%)
FCEL : 6.63 (-5.15%)
CVX : 196.82 (-0.08%)
HIMS : 24.77 (+3.90%)
NVO : 37.96 (-0.16%)
MTN : 131.74 (-2.64%)
HBAN : 15.21 (-1.74%)
UNF : 273.31 (+0.16%)
COST : 1,008.43 (+0.51%)
Should You Chase the Rally in Hims & Hers Stock Today?

Hims & Hers shares extend gains as Eli Lilly warns impurity it discovered in compounded versions of its weight-loss drug has health implications. Here’s why HIMS stock isn’t worth owning here.

HIMS : 24.77 (+3.90%)
NVO : 37.96 (-0.16%)
LLY : 985.08 (+0.80%)
1 Value Stock with Exciting Potential and 2 We Ignore

1 Value Stock with Exciting Potential and 2 We Ignore

HIMS : 24.77 (+3.90%)
LXFR : 11.60 (-0.34%)
EGHT : 2.09 (-0.95%)
3 Big Reasons to Love Hims & Hers Health (HIMS)

3 Big Reasons to Love Hims & Hers Health (HIMS)

HIMS : 24.77 (+3.90%)
Hims & Hers Names Kathryn Beiser as Chief Communications Officer

The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world’s leading consumer health platform in its next phase of growth

HIMS : 24.77 (+3.90%)
Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal

Hims & Hers shares surged 46% after partnering with Novo Nordisk to offer FDA-approved Ozempic and Wegovy, moving away from compounded GLP-1 alternatives.

HIMS : 24.77 (+3.90%)
NVO : 37.96 (-0.16%)
Introducing Hims & Hers Benefits, Unlocking Health & Wellness Discounts for Subscribers

The program debuts with Prenuvo and Eight Sleep, providing discounts on advanced diagnostics and sleep technology

HIMS : 24.77 (+3.90%)
Stock Index Futures Turn Lower as Bond Yields Climb

March S&P 500 E-Mini futures (ESH26) are down -0.15%, and March Nasdaq 100 E-Mini futures (NQH26) are down -0.14% this morning, giving up earlier gains driven by President Trump’s remarks on the Iran...

KLAC : 1,418.64 (+0.64%)
GOOGL : 302.28 (-0.42%)
NVDA : 180.25 (-1.58%)
SNDK : 661.62 (+6.92%)
HIMS : 24.77 (+3.90%)
MU : 426.13 (+5.13%)
ORCL : 155.11 (-2.54%)
ESH26 : 6,636.00s (-0.62%)
TSM : 338.31 (+0.48%)
VOW3.D.DX : 89.500 (-3.12%)
OXY : 57.88 (-0.91%)
TSLA : 391.20 (-0.96%)
Stocks Close Higher After President Trump says Iran War is "Pretty Much" Complete

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.71%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.13%. March E-mini...

NVDA : 180.25 (-1.58%)
GOOGL : 302.28 (-0.42%)
MPC : 226.18 (-1.69%)
UAL : 86.60 (+0.08%)
NOC : 733.71 (-0.35%)
CVX : 196.82 (-0.08%)
$SPX : 6,632.19 (-0.61%)
HIMS : 24.77 (+3.90%)
LYV : 153.97 (-3.96%)
AAL : 10.30 (-2.37%)
$IUXX : 24,380.73 (-0.62%)
NQH26 : 24,394.25s (-0.67%)
Hims & Hers Stock Is Challenging Its 50-Day Moving Average. Should You Bet on a Turnaround Here?

Hims & Hers shares soared as Novo Nordisk dropped its GLP-1 lawsuit. But there’s reason to still sell HIMS stock today. Find out more!

HIMS : 24.77 (+3.90%)
NVO : 37.96 (-0.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Hims & Hers Health Inc. is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling medical care for numerous conditions related to mental health, sexual health, dermatology, primary care and more. Hims & Hers Health Inc., formerly known as Oaktree...

See More

Key Turning Points

3rd Resistance Point 26.88
2nd Resistance Point 25.85
1st Resistance Point 25.31
Last Price 24.77
1st Support Level 23.74
2nd Support Level 22.71
3rd Support Level 22.17

See More

52-Week High 70.43
Fibonacci 61.8% 48.77
Fibonacci 50% 42.08
Fibonacci 38.2% 35.40
Last Price 24.77
52-Week Low 13.74

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar